TATAA Biocenter Partners with SimplicityBio
News Oct 26, 2016
TATAA Biocenter has partnered with SimplicityBio to offer complete solutions for biomarker discovery, signature optimization and validation. The partnership offers a complete solution comprising biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation leading to robust and reliable biomarker signatures for diagnostics, prognostics and theranostics. Platforms include microarrays, qPCR, dPCR and NGS and virtually any kind of biomarkers with emphasis on mRNA, microRNA, lncRNA, DNA (SNP, CNV, methylation, cfDNA), protein and circulating tumor cells.
“Leveraging on our experience of quality control and standardization of molecular analyses we design experimental protocols and generate data of highest quality for our clients. Combining our data with first class biomarker analyses provided by SimplicityBio, we provide our clients with complete solutions” says Mikael Kubista, President of TATAA Biocenter.
"We’re always looking to partner with innovative companies that are true leaders in the genomic services industry, and TATAA Biocenter is exactly that. TATAA Biocenter supports clients with design and validation of assays and generates genomic data of highest quality based on their accredited pipelines. Those data are perfect inputs for our biomarker discovery and modelling pipelines” said Dr. Matthew Hall CSO of SimplicityBio. Together we offer our clients the most powerful platform for biomarker discover, validation and confirmation currently available.
Ancient Genes Take on New Functions as Master RegulatorsNews
Researchers find that about 60 lncRNA genes in mammals – or 2% to 3% of lncRNAs shared by humans and other mammalian species – appear to be derived from ancestral, protein-coding genes.READ MORE
CRISPR Reveals the Sugary Secrets of the Cancer-related Notch ProteinNews
New research shows that the fucose and glucose modifications serve as quality-control markers that allow Notch to be transported to its final destination in the cell membrane.READ MORE
Metabolic Classification of Human Hepatoblastoma UncoveredNews
EPFL scientists have now found metabolic differences between hepatoblastoma subtypes, and identified several biomarkers that can help obtain more accurate subtyping of the disease.READ MORE